Literature DB >> 1943931

The cost of asthma in New South Wales.

C M Mellis1, J K Peat, A E Bauman, A J Woolcock.   

Abstract

OBJECTIVE: To determine the economic cost of asthma to the New South Wales community.
DESIGN: Direct costs (both health-care and non-health-care) plus indirect costs (loss of productivity) were estimated from various sources to assess retrospectively the dollar costs of asthma. Intangible costs (such as quality of life) were not included.
SETTING: Estimates of costs were made at all levels of medical care of asthma patients, including inpatient and outpatient hospitalisations, emergency department visits, and visits to general practitioners and specialist physicians, plus costs of pharmaceuticals, nebulisers and home peak-flow monitoring devices. The cost of time lost by the patient attending for medical visits and loss of productivity due to absence from employment as a result of asthma were also included.
RESULTS: The total cost of asthma in New South Wales was $209 million in 1989. This was made up of $142 million in direct health-care costs, $19 million in direct non-health-care costs and $48 million in indirect costs.
CONCLUSION: Although we believe that our estimate is an underestimate of the true dollar cost of this disease to the community, it represents $769 per asthmatic person per year, assuming a current prevalence rate for asthma in New South Wales of 6%. The cost effectiveness of any new treatment of asthma should be estimated to ensure that the economic cost to the community does not rise unnecessarily.

Entities:  

Mesh:

Year:  1991        PMID: 1943931     DOI: 10.5694/j.1326-5377.1991.tb93888.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  17 in total

1.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

Review 2.  The economic costs of asthma: a review and conceptual model.

Authors:  K B Weiss; S D Sullivan
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

3.  Comparison of nebulised magnesium sulphate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study.

Authors:  P Aggarwal; S Sharad; R Handa; S N Dwiwedi; M Irshad
Journal:  Emerg Med J       Date:  2006-05       Impact factor: 2.740

4.  Calculating the cost of asthma in Canada.

Authors:  W Ungar
Journal:  CMAJ       Date:  1996-10-01       Impact factor: 8.262

Review 5.  Clinical management of asthma in the 1990s. Current therapy and new directions.

Authors:  P Jain; J A Golish
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 6.  Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.

Authors:  H M Lamb; C R Culy; D Faulds
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 7.  The cost of asthma: can it be reduced?

Authors:  C M Mellis; J K Peat; A J Woolcock
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 8.  Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.

Authors:  D H Peters; D Faulds
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

Review 9.  Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?

Authors:  T D Holimon; C C Chafin; T H Self
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 10.  Economic burden of asthma: a systematic review.

Authors:  Katayoun Bahadori; Mary M Doyle-Waters; Carlo Marra; Larry Lynd; Kadria Alasaly; John Swiston; J Mark FitzGerald
Journal:  BMC Pulm Med       Date:  2009-05-19       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.